The goal of this pilot clinical trial is to learn if early restart of renin-angiotensin system inhibitor (RASi) medications is feasible and well-tolerated in hospitalized patients with acute kidney injury (AKI). Researchers will compare early RASi restart to usual care.
Study participants will restart RASi per study protocol, obtain a lab test in 1-2 weeks if RASi restarted in the hospital and not collected as part of routine care, and answer questions at the 90-day follow-up.
Age ≥ 18 years
Pre-admission RASi use for Class I indication (e.g., heart failure, kidney disease)
RASi stopped in the setting of AKI (defined by ≥1.5x baseline SCr)
AKI in recovery (defined by a decrease in SCr by ≥0.3mg/dL from peak)
RASi allergy or contraindication (i.e., angioedema, bilateral renal artery stenosis)
Ongoing dialysis requirement
Pregnant or breastfeeding
Prisoner
University of California, San Francisco
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator